阿伐可泮真实世界肝毒性:美国风湿病注册登记中严重药物性肝损伤的确诊病例
基于美国风湿病有效性信息学系统注册登记,238例接受阿伐可泮治疗的AAV患者中,肝酶升高不常见,但确认2例(0.8%)药物性肝损伤,RUCAM评分均为9分(高度可能),其中1例经组织学证实为严重肝细胞损伤。结果支持早期密切监测肝功能。
要点
- 阿伐可泮治疗期间肝酶升高发生率低,但可出现严重DILI。
- 2例DILI的RUCAM评分均为9分,提示高度很可能因果关系。
- 首次肝酶筛查中位时间32天,平均检测间隔125天。
核心结论
- 美国AAV队列中阿伐可泮治疗期间肝酶升高不常见,但仍发生严重DILI。
- 研究结果支持在持续监管再评估期间进行警惕性早期监测并充分告知潜在风险。
研究设计与样本
- 数据来自风湿病有效性信息学系统注册登记,识别2021年10月至2025年3月至少开具一次阿伐可泮处方的AAV患者。
- 共纳入238例接受阿伐可泮治疗的AAV患者,肝酶升高按FDA指南定义,风险人时根据处方信息估算。
- 达到实验室阈值的患者接受RUCAM评估。
主要发现
- 238例患者中,5例AST升高、3例ALT升高、4例碱性磷酸酶升高、2例总胆红素升高。
- AST升高发生率为4.24/100人年(95%CI 1.77-10.19),ALT为2.67/100人年(95%CI 0.86-8.27),碱性磷酸酶为3.56/100人年(95%CI 1.34-9.49),总胆红素为1.80/100人年(95%CI 0.45-7.19)。
- 确认2例DILI(0.8%),RUCAM评分均为9分(高度很可能因果关系),其中1例经组织学证实为严重肝细胞损伤。
- 首次肝酶筛查中位时间为32天,平均检测间隔为125天。
关键数值与推荐
- 肝酶升高定义:AST或ALT>3×正常上限(ULN),碱性磷酸酶>2×ULN,总胆红素>2 mg/dL。
- RUCAM评分9分定义为高度很可能因果关系。
临床怎么用
- 对接受阿伐可泮治疗的AAV患者应进行早期肝功能监测。
- 治疗前及治疗中应与患者讨论潜在肝毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Avacopan, an oral C5a receptor inhibitor, was approved for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in 2021. Following US Food and Drug Administration (FDA) reports of 76 worldwide drug-induced liver injury (DILI) cases (66 in Japan and five in the United States), the agency requested market withdrawal, which the manufacturer declined. US risk has not been quantified using real-world data. This study estimated the incidence of hepatic enzyme elevations among US avacopan users and characterized confirmed DILI cases. METHODS: Data came from the Rheumatology Informatics System for Effectiveness registry. We identified patients with AAV with at least one avacopan prescription (October 2021-March 2025). Hepatic enzyme elevations were defined per FDA guidance (aspartate transferase [AST] or alanine transaminase [ALT] >3 × the upper limit of normal [ULN], alkaline phosphatase [Alk Phos] >2 × ULN, and total bilirubin >2 mg/dL). Person-time at risk was estimated from prescribing information. Patients meeting elevated laboratory thresholds underwent Roussel Uclaf Causality Assessment Method (RUCAM) evaluation. RESULTS: Among 238 patients with AAV treated with avacopan, liver enzyme elevations during treatment were uncommon: five patients had elevated AST, three ALT, four Alk Phos, and two total bilirubin, with incidence rates of 4.24 (95% confidence interval [CI] 1.77-10.19), 2.67 (95% CI 0.86-8.27), 3.56 (95% CI 1.34-9.49), and 1.80 (95% CI 0.45-7.19) per 100 person-years, respectively. Median time to first hepatic enzyme screening was 32 days, with testing intervals averaging 125 days. Two DILI cases (0.8%) were identified, both with RUCAM scores of 9 (highly probable causality), including one with histologically confirmed severe hepatocellular injury. CONCLUSION: Hepatic enzyme elevations during avacopan therapy were infrequent in this US cohort, yet severe DILI occurred. Findings support vigilant early monitoring and informed discussions of potential risks during ongoing regulatory reassessment.
引用
- Roberts ET, Dadabhoy D, Antolini R, et al. Hepatotoxicity of Avacopan: Real-World Incidence and Confirmed Cases of Severe Drug-Induced Liver Injury in a US National Rheumatology Registry. Arthritis Rheumatol. 2026. PMID: 42635291. doi:10.1002/art.70304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。